SHTDF — Sinopharm Co Balance Sheet
0.000.00%
- $7.40bn
- $22.65bn
- CNY584.51bn
- 84
- 98
- 59
- 95
Annual balance sheet for Sinopharm Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 50,217 | 43,541 | 55,327 | 63,814 | 56,865 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 149,507 | 176,321 | 175,787 | 189,855 | 206,768 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 267,610 | 290,922 | 319,406 | 336,835 | 347,448 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 18,896 | 19,408 | 19,647 | 19,898 | 19,632 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 311,237 | 335,412 | 364,775 | 383,395 | 392,831 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 203,977 | 219,307 | 234,963 | 241,491 | 250,376 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 254,878 | 273,526 | 296,707 | 308,813 | 313,947 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 56,359 | 61,886 | 68,069 | 74,582 | 78,884 |
| Total Liabilities & Shareholders' Equity | 311,237 | 335,412 | 364,775 | 383,395 | 392,831 |
| Total Common Shares Outstanding |